AJDRAJNR - American Journal of Neuroradiology

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fitzsimmons, B.-F. M.
Right arrow Articles by Lazar, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fitzsimmons, B.-F. M.
Right arrow Articles by Lazar, R. M.

American Journal of Neuroradiology 24:1456-1460, August 2003
© 2003 American Society of Neuroradiology

Technical Note
INTERVENTIONAL

Neurobehavioral Differences in Superselective Wada Testing with Amobarbital versus Lidocaine

Brian-Fred M. Fitzsimmonsa,c, Randolph S. Marshalla, John Pile-Spellmanb,c and Ronald M. Lazara,c

a Cerebrovascular Center of the Neurological Institute, Department of Neurology, Columbia University College of Physicians and Surgeons, New York, NY
b Cerebrovascular Center of the Neurological Institute, Department of Radiology, Columbia University College of Physicians and Surgeons, New York, NY
c Cerebrovascular Center of the Neurological Institute, Department of Neurosurgery, Columbia University College of Physicians and Surgeons, New York, NY

Address correspondence and reprint requests to Dr. Brian-Fred M. Fitzsimmons, Divisions of Stroke and Neurological Intensive Care, 710 West 168th Street, Box 185, New York, NY 10032

Summary: Four patients with cerebral arteriovenous malformations (AVMs) underwent superselective Wada testing with intraarterial amobarbital and lidocaine before embolization. In all four patients, the use of lidocaine detected clinically significant neurologic deficits that amobarbital alone did not, likely because of the pharmacodynamic differences of the two agents. The use of lidocaine with amobarbital for superselective Wada testing in patients with cerebral AVMs may improve the sensitivity and predictive value of this test in the future.






Copyright © 2010 by the American Society of Neuroradiology. Print ISSN: 0195-6108 Online ISSN: 1936-959X